These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

899 related items for PubMed ID: 8740244

  • 1. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P, Echevaría-Vázquez D, Petrov V.
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [Abstract] [Full Text] [Related]

  • 2. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin.
    Lijnen P, Celis H, Desager JP, Fagard R.
    J Hum Hypertens; 1995 Jul; 9(7):557-64. PubMed ID: 7562885
    [Abstract] [Full Text] [Related]

  • 3. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems.
    Lijnen P, Celis H, Fagard R, Staessen J, Amery A.
    J Hypertens; 1994 Jan; 12(1):59-64. PubMed ID: 8157945
    [Abstract] [Full Text] [Related]

  • 4. Transmembrane cationic fluxes in erythrocytes of diabetics and normal men.
    Lijnen P, Fenyvesi A.
    Methods Find Exp Clin Pharmacol; 1994 Jan; 16(1):37-47. PubMed ID: 8164472
    [Abstract] [Full Text] [Related]

  • 5. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
    Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, Inoue T, Morii H.
    Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
    [Abstract] [Full Text] [Related]

  • 6. Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia.
    Koter M, Franiak I, Broncel M, Chojnowska-Jezierska J.
    Can J Physiol Pharmacol; 2003 May; 81(5):485-92. PubMed ID: 12774855
    [Abstract] [Full Text] [Related]

  • 7. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989 May; 11(2):247-57. PubMed ID: 2736571
    [Abstract] [Full Text] [Related]

  • 8. Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes.
    Rabini RA, Polenta M, Staffolani R, Tocchini M, Signore R, Testa I, Mazzanti L.
    Exp Mol Pathol; 1993 Aug; 59(1):51-7. PubMed ID: 8262165
    [Abstract] [Full Text] [Related]

  • 9. [Pravastatin effects on lipoproteins, Lp (a), apo B and apo A-1 in patients with primary hypercholesterolemia].
    Novazzi JP, Fonseca FA, Feres MC, da Silva RC, Lima JC, Martinez TL.
    Arq Bras Cardiol; 1994 Jun; 62(6):395-8. PubMed ID: 7826229
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia].
    Schwartzkopff W, Bimmermann A, Schleicher J.
    Arzneimittelforschung; 1990 Dec; 40(12):1322-7. PubMed ID: 2128866
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A, Rovellini A, Fiorenza AM, Sommariva D.
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [Abstract] [Full Text] [Related]

  • 14. Lecithin: cholesterol acyltransfer, dyslipoproteinaemia and membrane lipids in uraemia.
    Gillett MP, Obineche EN, El-Rokhaimi M, Lakhani MS, Abdulle A, Sulaiman M.
    J Nephrol; 2001 Jun; 14(6):472-80. PubMed ID: 11783603
    [Abstract] [Full Text] [Related]

  • 15. The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy.
    Chan P, Lee CB, Lin TS, Ko JT, Pan WH, Lee YS.
    Am J Hypertens; 1995 Nov; 8(11):1099-104. PubMed ID: 8554733
    [Abstract] [Full Text] [Related]

  • 16. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR.
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [Abstract] [Full Text] [Related]

  • 17. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
    Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, Witztum JL, FitzGerald GA, Rader DJ.
    J Am Coll Cardiol; 2008 Apr 29; 51(17):1653-62. PubMed ID: 18436117
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of pravastatin in hypertensive hypercholesterolaemic patients on antihypertensive drug therapy.
    Celis H, Lijnen P, Fagard R, Staessen J, Thijs L, Amery A.
    J Hum Hypertens; 1994 Jul 29; 8(7):525-30. PubMed ID: 7932517
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
    McPherson R, Bedard J, Connelly P, Curnew G, Davignon J, Echenberg D, Lavin P, Leiter L, Lenis J, McQueen M.
    Clin Ther; 1992 Jul 29; 14(2):276-91. PubMed ID: 1611649
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.